Pelubiprofen - Daewon Pharmaceutical
Alternative Names: CS 670; DW-330; DW-330SR; DW1809; DW9801; Pelubi; Pelubiprofen sustained release; RS 2131Latest Information Update: 31 Mar 2021
At a glance
- Originator Sankyo
- Developer Daewon Pharmaceutical; Sankyo
- Class Analgesics; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Back pain; Osteoarthritis
- Phase III Fever
- No development reported Acute pain; Musculoskeletal pain; Rheumatoid arthritis
- Discontinued Rheumatic disorders
Most Recent Events
- 31 Mar 2021 No development reported - Phase-III for Acute pain in South Korea (PO) (NCT03874247)
- 09 Sep 2020 Daewon Pharmaceutical plans a phase III trial for Dysmenorrhoea in September 2020 , (NCT04541134)
- 08 Sep 2020 Daewon Pharmaceutical completes phase I trial in healthy volunteers in South Korea (NCT05214690)